Navigation Links
Personalized treatment may help some liver cancer patients
Date:10/22/2010

A more personalized treatment for people with a type of metastatic liver cancer --hepatocellular carcinoma -- may be possible by targeting the protein c-Met, according to Penn State College of Medicine researchers. Hepatocellular carcinoma (HCC) is the number three cause of cancer deaths in the world.

Hanning You, M.D., Ph.D., postdoctoral fellow, and C. Bart Rountree, M.D., assistant professor of pediatrics and pharmacology, targeted c-Met, a known receptor for hepatocyte growth factor, the substance that appears to drive liver cancer metastasis. In a pre-clinical translational study, they show that c-Met is overexpressed in metastatic liver cancer cells and is associated with a poor prognosis.

"In addition to finding that c-Met is a significant biomarker for liver cancer, we conducted an analysis of six published manuscripts and 1,051 patients," said You. "Through this analysis we demonstrated and confirmed that c-Met activation is strongly associated with poor prognosis and aggressive features in patients with liver cancer tumors."

Currently, physicians treat hepatocellular carcinoma with a "one size fits all" approach, so targeting c-Met may be an effective therapy for some patients.

"The five-year-survival of HCC is only 2 percent when diagnosed after metastasis," said Rountree. "Sorafenib, the most recently approved mediation for advanced HCC, benefits patients with an extra two months survival."

By targeting c-Met, researchers suppressed tumor growth and proliferation in a mouse model. They believe that molecular profiling will allow better treatment for the 45 percent of HCC patients who have c-Met positive tumors.

The research team is now looking to apply their findings to HCC in humans. The lab has applied to the National Cancer Institute to join a phase I trial using a c-Met inhibitor for advanced HCC.

"We are also working to build a second trial where we will establish a molecular profile of HCC patients before we start treatment, and then only give the c-Met inhibitor to the patients with a c-Met positive tumor, in effect personalizing their therapy," Rountree said.


'/>"/>

Contact: Matt Solovey
msolovey@hmc.psu.edu
717-531-8606
Penn State
Source:Eurekalert

Related medicine news :

1. Perspectives on improving patient care: Genetics, personalized medicine, and behavioral intervention
2. Penn receives $12 million NIH grant to research personalized approach to smoking cessation
3. Personalized medicine: Molecular imaging predicts treatment success in many cancers
4. Pilot study supports adolescent diabetes patients through personalized text messages
5. Tumor target suggests personalized treatment for melanoma
6. Advances in personalized medicine take center stage
7. Myth Debunked: Baby Shower Gifts CAN Be Personalized Without Knowing Name Or Gender
8. DSM Personalized Nutrition Webinar Examines Ways to Build Engagement in Wellness Programs
9. Pediatric personalized medicine takes center stage at first-of-its-kind international conference
10. Personalized medicine for cancer patients in a new technology era
11. TGen Drug Development partners with Horizon Discovery for integrated personalized medicine service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, ... Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments in ... the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... ... BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a ... an hour by 2020 and then adjusting it yearly to increase at the same rate ... assure the wage floor does not erode again, and make future increases more predictable. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology: